Clinical Trials Arena11h
Compass’s tovecimig meets primary endpoint in Phase II/III BTC trial
Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with ...
Clinical Trials Arena9h
Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia
Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...
Clinical Trials Arena13h
Yingli Pharma gains FDA approval for Phase III trial of r/r PTCL drug candidate
Yingli Pharma has obtained US FDA approval for a Phase III trial of linperlisib for R/R peripheral T-cell lymphoma (PTCL).
Clinical Trials Arena12h
Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback
The pivotal, Phase III study will evaluate the change in average daily “OFF” time in Parkinson's patients dosed with ...
Clinical Trials Arena12h
Moleculin Biotech begins dosing subjects in combination therapy trial for AML
Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid ...
Clinical Trials Arena7h
Placing the patient at the centre of the drug development paradigm
Patient engagement through advisory boards, surveys, and listening sessions can help address industry challenges like trial delays.
Clinical Trials Arena6h
Desentum to advance pollen allergy vaccine after positive Phase I trial
Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, DM-101PX.